<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04190433</url>
  </required_header>
  <id_info>
    <org_study_id>19-007547</org_study_id>
    <nct_id>NCT04190433</nct_id>
  </id_info>
  <brief_title>AuTophagy Activation for Cardiomyopathy Due to Anthracycline tReatment (ATACAR)Trial</brief_title>
  <official_title>AuTophagy Activation for Cardiomyopathy Due to Anthracycline tReatment (ATACAR)Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Researchers are comparing two drug therapy plans to treat heart function changes after&#xD;
      anthracycline-based treatment for lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, parallel-group clinical trial in lymphoma patients with reduced cardiac function (left ventricular ejection fraction &lt;50%) after anthracycline-based chemotherapy with two study groups:&#xD;
Group 1: Carvedilol and Lisinopril titrated to maximally tolerated doses as per standard practice Group 2: Pravastatin and Spironolactone in addition to maximally titrated Carvedilol and Lisinopril doses</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac function changes</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>Change in left ventricular ejection fraction (LVEF)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Standard Therapy Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carvedilol and Lisinopril titrated to maximally tolerated doses as per standard practice</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expanded Therapy Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pravastatin 40 mg per day and Spironolactone 25 mg per day in addition to maximally titrated Carvedilol and Lisinopril doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carvedilol</intervention_name>
    <description>Up-titrated to maximum tolerated doses as per standard clinical practice</description>
    <arm_group_label>Expanded Therapy Group</arm_group_label>
    <arm_group_label>Standard Therapy Group</arm_group_label>
    <other_name>Coreg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lisinopril</intervention_name>
    <description>Up-titrated to maximum tolerated doses as per standard clinical practice</description>
    <arm_group_label>Expanded Therapy Group</arm_group_label>
    <arm_group_label>Standard Therapy Group</arm_group_label>
    <other_name>Zestril</other_name>
    <other_name>Prinivil</other_name>
    <other_name>Qbrelis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pravastatin</intervention_name>
    <description>40 mg per day</description>
    <arm_group_label>Expanded Therapy Group</arm_group_label>
    <other_name>Pravachol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone</intervention_name>
    <description>25 mg per day</description>
    <arm_group_label>Expanded Therapy Group</arm_group_label>
    <other_name>CaroSpir</other_name>
    <other_name>Aldactone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  â‰¥18 years of age,&#xD;
&#xD;
          -  New diagnosis of reduced cardiac function&#xD;
&#xD;
          -  Prior anthracycline-based cancer therapy for lymphoma&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  History of HF of any class and type, or diagnosis of cardiomyopathy prior to&#xD;
             anthracycline therapy&#xD;
&#xD;
          -  On active therapy with a fibrate, niacin, or eplerenone&#xD;
&#xD;
          -  History of myopathy/rhabdomyolysis&#xD;
&#xD;
          -  History of statin intolerance&#xD;
&#xD;
          -  Active hyperlipidemia&#xD;
&#xD;
          -  History of gout&#xD;
&#xD;
          -  Active liver disease&#xD;
&#xD;
          -  Unexplained persistent elevations of serum transaminases&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Breast-feeding&#xD;
&#xD;
          -  Hyperkalemia&#xD;
&#xD;
          -  Addison disease&#xD;
&#xD;
          -  eGFR &lt;30 mL/minute/1.73 m2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joerg Herrmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sierra Slade</last_name>
    <phone>507-422-5433</phone>
    <email>slade.sierra@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Trevor Stromme</last_name>
    <phone>507-293-2754</phone>
    <email>stromme.trevor@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Referral Office</last_name>
      <phone>855-776-0015</phone>
      <email>mayocliniccancerstudies@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Joerg Herrmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials?_ga=2.255832640.97781284.1618936001-58282638.1618936001</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>December 5, 2019</study_first_submitted>
  <study_first_submitted_qc>December 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2019</study_first_posted>
  <last_update_submitted>May 7, 2021</last_update_submitted>
  <last_update_submitted_qc>May 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Joerg Herrmann, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carvedilol</mesh_term>
    <mesh_term>Lisinopril</mesh_term>
    <mesh_term>Spironolactone</mesh_term>
    <mesh_term>Pravastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

